JW Pharmaceutical Corporation (001060.KS) Stock

001060.KS logo

JW Pharmaceutical Corporation

001060.KSSouth Korea
Healthcare

Company profile

JW Pharmaceutical reported revenue of 775.30 billion KRW for fiscal year 2025, up 7.8% from fiscal year 2024, and net income of 61.51 billion KRW. That is a net profit margin of 7.9% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 199.88 billion KRW, up 7.9% from a year before. In Q1 2026 it reported net income of 27.48 billion KRW, against net income of 17.47 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 748.53 billion KRW in fiscal year 2023 to 775.30 billion KRW in fiscal year 2025, 1.8% a year on average. JW Pharmaceutical reports about 1,049 full-time employees.

What stands out

  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About JW Pharmaceutical Corporation

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases, and pancreatic cancer. The company also provides infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.

Largest shareholders

  • Jw Holdings Corporation47.65%
  • National Pension Service of Korea4.20%
  • Jw Pharmaceutical Corporation3.20%
  • Kyung-Ha Lee0.6105 %0.61%
  • Jung-ha Lee0.0605 %0.06%

Share of the company, as of September 25, 2026

Leadership

  • Young-Sub Shin — CEO, Head of Sales & Marketing and Inside Director, 62
  • Sung-Yeol Lee — CEO, Head of Product Development & Management and Director
  • Jae-Kwang Jeon — Head Managing Director and Head of Public Relation, 63
  • Hyun-seok Han — Head of Product Plant, 63
  • Kim Yong Kwan — Development Head & Internal Director

How much revenue does JW Pharmaceutical make?

JW Pharmaceutical reported 775.30 billion KRW in revenue for fiscal year 2025, up 7.8% from 719.38 billion KRW in fiscal year 2024. In Q1 2026 revenue was 199.88 billion KRW.

What companies are similar to JW Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chong Kun Dang Pharmaceutical Corp. (185750.KS), Boryung Corporation (003850.KS), Daewoong Co., Ltd. (003090.KS), Shinpoong Pharmaceutical Co.,Ltd (019170.KS).

How has JW Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 606.58 billion KRW; FY2022, 684.35 billion KRW; FY2023, 748.53 billion KRW; FY2024, 719.38 billion KRW; FY2025, 775.30 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,049
HeadquartersGwacheon-si, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
JW Gwacheon Tower, 38, Gwacheon-si, 13840
Phone
82 2 840 6777
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “JW Pharmaceutical Corporation (001060.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/001060.KS

LinkedInLinkedInXXYouTubeYouTube